KRAS and lung adenocarcinoma: Specifically, KRAS mutations (KRAS MT) are implicated in an estimated 30% of lung adenocarcinomas, a staggering 45% of metastatic colorectal cancers, and an even more alarming 90% of pancreatic ductal adenocarcinomas.[1–3] A noteworthy meta-analysis focusing on colorectal cancer illustrated a disconcerting picture, wherein progression-free survival (PFS) was notably compromised.